Postpartum cells derived from placental tissue, and methods of making and using the same
View Patent ↗Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.
1. An extracellular matrix composition comprising isolated human placenta-derived cells and extracellular matrix produced by a population of the isolated human placenta-derived cells, wherein the isolated human placenta-derived cells are derived from human postpartum placenta tissue substantially free of blood, wherein the placenta-derived cell self-renews and expands in culture, is multipotent, grows in about 5% to about 20% oxygen, and further comprises the following characteristics:
a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, HLA-A,B,C, and granulocyte chemotactic protein-2 (GCP-2);
b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP, DQ, as detected by flow cytometry; and
c) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 and renin.
2. The extracellular matrix composition of claim 1 , wherein the isolated human placenta-derived cell in the composition is a cryopreserved cell.
3. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell further comprises the following characteristics:
d) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry
e) secretes of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), interleukin 8 (IL8), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and
f) lack of secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), I309, and macrophage-derived chemokine (MDC), as detected by ELISA.
4. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is of a neonatal origin.
5. The extracellular matrix composition of claim 1 , wherein said placenta-derived cell is of a maternal origin.
6. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell has the ability to differentiate into a mesodermal, ectodermal, or endodermal phenotype.
7. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell can undergo at least 40 population doublings in culture.
8. The extracellular matrix composition claim 1 , further comprising genetically engineering the placenta-derived cell to produce a protein of interest.
9. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6074.
10. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6075.
11. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6079.
12. A matrix comprising the extracellular matrix composition of claim 1 .
13. The matrix of claim 12 , wherein said matrix is a three-dimensional scaffold.
14. The matrix of claim 13 comprising a nonwoven scaffold, a 35/65 PCL/PGA foam, an in situ polymerizable gel, or a self-assembling peptide hydrogel.